Care Capital: VC Post-2001
This article was originally published in Start Up
Care Capital's focus on later-stage programs--driven by its ex-Big Pharma partners' own expertise in more advanced development and marketing--happily coincided with the lower-risk, closer-to-market models which have become fashionable with private and public investors since the 2001 downturn. Does this VC firm have the right model at the right time?
You may also be interested in...
Discovery research is an ever more difficult investment to justify, so companies are placing greater emphasis on mining discoveries that have already been made but whose real value remains unexploited. Big Pharma, in part inhibited by habit and current infrastructure, has not moved aggressively in the new direction-but the jumpstart model now dominates small-company strategies and will increasingly translate into the rest of the industry.
Top executives from Big Pharmas, like Jan Leschley of SmithKline and Tony Wild of Warner-Lambert, are now taking a run at venture capital--figuring that their rolodexes and understanding of drug-company requirements will give them a big advantage in starting new companies. The question is whether these contacts will be of much help during periods when financing is difficult--that's when real VC experience comes in handy.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.